Duos Technologies Group, Inc.

DUOT

Nasdaq; business equipment; SIC 7372, Services-Prepackaged Software; CIK 0001396536

D/E

on the D/E boundary of 469 graded peers in business equipm...

rank 370 of 469; percentile 78.8; sampling error 2.3 points; lower is stronger

A B C D E

D/E, the sloth



Scoreboard	
Profitability	E percentile 86.9
Solvency	C percentile 54.3
Growth and financing	B/C percentile 38.8
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $63.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, late filer; fortress balance sh... not computable: short runway, distress
Inputs computable	8 of 13
Graded from	filings received through Mar 31, 2026 234 days before the rescan; latest periodic filing 10-Q received Nov 16, 2026
Last close	$2.97 2026-11-19; market equity $101.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

was incorporated in Florida on May 31, 1994. Our original business operations consisted of consulting services for asset management of large corporate data centers and the development and licensing of information technology ("IT") asset management software. In late 2014, ISA entered negotiations with Duos Technologies, Inc. ("duostech?") for the purposes of executing a merger between the two organizations (also known as a "reverse triangular merger"). Incorporated under the laws of Florida on November 30, 1990, duostech? operated in various industry segments, specializing in the design, development and deployment of proprietary technology applications and turn-key engineered systems.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 86.9						
Gross profitability	12.4%	29.3%		80.7	513	2025-12-31
Return on invested capital	not computable	11.0%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	8.0%	(7.3%)		94.0	567	2025-12-31
Gross margin stability, five years	9.1 pts	2.3 pts		85.9	406	2025-12-31
Solvency, sleeve percentile 54.3						
Altman Z double-prime	(0.69)	2.19		61.6	517	2025-12-31
Net debt to EBITDA	not computable	1.08x				
EBITDA must exceed $100,000						
Interest coverage	not computable	4.90x				
interest expense must exceed $100,000						
Current ratio	2.08x	1.98x		47.0	601	2025-12-31
Growth and financing, sleeve percentile 38.8						
Revenue growth, three-year compound	21.6%	6.6%		17.3	503	2025-12-31
Free cash flow growth, three-year compound	not computable	17.5%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	16.2%				
one or more required annual facts are missing						
Asset growth, three years	69.2%	5.1%		4.0	520	2025-12-31
Net share issuance, one year	156.3%	0.5%		95.0	405	2026-03-27

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 156.3%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 132,768 USD; Altman Z is not used

Among 469 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
365	Harvard Bioscience Inc. (HBIO)	77.8	D/E	
366	Marchex Inc. (MCHX)	78.0	D/E	
367	Airgain Inc. (AIRG)	78.2	D/E	
368	C3.ai, Inc. (AI)	78.4	D/E	
369	GoodRx Holdings, Inc. (GDRX)	78.6	D/E	late filer
370	Duos Technologies Group, Inc. (DUOT)	78.8	D/E	dilution, late filer, fortress balance sheet
371	Thermo Fisher Scientific Inc. (TMO)	79.1	D/E	
372	Asure Software Inc. (ASUR)	79.3	D/E	
373	SmartRent, Inc. (SMRT)	79.5	D/E	
374	Definitive Healthcare Corp. (DH)	79.7	D/E	fortress balance sheet
375	ZoomInfo Technologies Inc. (GTM)	79.9	D/E	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(14.6%)	(2.2%)	39
Distance from 52-week high	(79.6%)	(38.6%)	10
EBIT to enterprise value	(9.6%)	1.8%	17
Free cash flow yield	(36.5%)	3.0%	11
Book value to price	2.06	0.29	92
Sales to price	0.26	0.33	44
Composite equity issuance, five years	227.2%	4.3%	95
Relative strength against the sector, log excess return	(0.43)	(0.29)	39
Twelve-month failure probability, CHS model	not computable	0.05%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	4 (10-Q received Nov 16, 2026)
Median daily dollar volume, 63 sessions	$5.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$7.9M	2025-12-31	2026-03-31	10-K	26-000405
2	assets	us-gaap:Assets	$63.4M	2025-12-31	2026-03-31	10-K	26-000405
3	net income	us-gaap:NetIncomeLoss	-$9.8M	2025-12-31	2026-03-31	10-K	26-000405
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$13.7M	2025-12-31	2026-03-31	10-K	26-000405
5	assets	us-gaap:Assets	$35.0M	2024-12-31	2026-03-31	10-K	26-000405
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$27.0M	2025-12-31	2026-03-31	10-K	26-000405
7	gross profit	us-gaap:GrossProfit	$469,215	2024-12-31	2026-03-31	10-K	26-000405
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.3M	2024-12-31	2026-03-31	10-K	26-000405
9	gross profit	us-gaap:GrossProfit	$1.3M	2023-12-31	2025-03-31	10-K	25-000555
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.5M	2023-12-31	2025-03-31	10-K	25-000555
11	gross profit	us-gaap:GrossProfit	$4.7M	2022-12-31	2024-04-01	10-K	24-000473
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.0M	2022-12-31	2024-04-01	10-K	24-000473
13	gross profit	us-gaap:GrossProfit	$2.0M	2021-12-31	2023-03-31	10-K	23-000241
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$8.3M	2021-12-31	2023-03-31	10-K	23-000241
15	current assets	us-gaap:AssetsCurrent	$23.1M	2025-12-31	2026-03-31	10-K	26-000405
16	current liabilities	us-gaap:LiabilitiesCurrent	$11.1M	2025-12-31	2026-03-31	10-K	26-000405
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$84.2M	2025-12-31	2026-03-31	10-K	26-000405

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

18	operating income	us-gaap:OperatingIncomeLoss	-$9.8M	2025-12-31	2026-03-31	10-K	26-000405
19	book equity	us-gaap:StockholdersEquity	$48.6M	2025-12-31	2026-03-31	10-K	26-000405
20	liabilities	us-gaap:Liabilities	$14.9M	2025-12-31	2026-03-31	10-K	26-000405
21	total debt	us-gaap:LongTermDebt	$41,608	2016-12-31	2018-04-02	10-K	18-000285
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$174,376	2016-12-31	2018-04-02	10-K	18-000285
23	operating income	us-gaap:OperatingIncomeLoss	-$1.7M	2016-12-31	2018-04-02	10-K	18-000285
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$41,398	2016-12-31	2018-04-02	10-K	18-000285
25	operating income	us-gaap:OperatingIncomeLoss	-$11.4M	2023-12-31	2025-03-31	10-K	25-000555
26	interest expense	us-gaap:InterestExpense	$7,159	2023-12-31	2024-04-01	10-K	24-000473
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$23.7M	2025-12-31	2026-03-31	10-K	26-000405
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.5M	2024-12-31	2026-03-31	10-K	26-000405
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.8M	2024-12-31	2026-03-31	10-K	26-000405
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.7M	2023-12-31	2025-03-31	10-K	25-000555
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$496,686	2023-12-31	2025-03-31	10-K	25-000555
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$7.9M	2022-12-31	2024-04-01	10-K	24-000473
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$344,915	2022-12-31	2024-04-01	10-K	24-000473
34	assets	us-gaap:Assets	$12.8M	2023-12-31	2025-03-31	10-K	25-000555
35	assets	us-gaap:Assets	$13.1M	2022-12-31	2024-04-01	10-K	24-000473
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	29,542,860	2026-03-27	2026-03-31	10-K	26-000405
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,524,545	2025-03-28	2025-03-31	10-K	25-000555

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.